Bourla said he spent Tuesday morning reviewing new data from various Covid vaccine studies, including one looking at the effects of a fourth dose of the currently available vaccine, as well as a new formulation that will protect against multiple coronavirus variants.
“They look encouraging,” Bourla said in an interview on Bloomberg Television’s “Balance of Power With David Westin,” noting that Pfizer still needs to collect more information.
Pandemic concerns are abating as the
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.